-
Mashup Score: 20ESMO 2023 GI Cancer Highlights – Codebreak300, CABINET, GASTFOX - 6 month(s) ago
In discussion with Dr. Rachna Shroff, covering the ESMO 2023 GI Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. Shroff: – Codebreak300 – Sotorasib plus Panitumumab in KRAS G12C-Mutated Metastatic Colorectal Cancer – CABINET – Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus […]
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 20ESMO 2023 GI Cancer Highlights – Codebreak300, CABINET, GASTFOX - 6 month(s) ago
In discussion with Dr. Rachna Shroff, covering the ESMO 2023 GI Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. Shroff: – Codebreak300 – Sotorasib plus Panitumumab in KRAS G12C-Mutated Metastatic Colorectal Cancer – CABINET – Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus […]
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet-
#ESMO23 GI Highlights w/ @rachnatshroff - #CodeBreak300 - #CABINET - #GASTFOX Full 📢: - https://t.co/oO0ErxWu5B - https://t.co/bqb1o0FiD7 - Also on the “Oncology Brothers” podcast #MedTwitter #OncTwitter @myESMO #gism #crcsm @TargetedOnc https://t.co/yTRCLR3vYq
-
-
Mashup Score: 38ESMO 2023 Lung Cancer - Chapter 2 Highlights – PAPILLON, MARIPOSA, MARIPOSA-2, LIBRETTO-431 - 6 month(s) ago
In discussion with Dr. Alexander Spira, covering the ESMO 2023 Lung Cancer Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Spira: – PAPILLON – Amivantamab Plus Chemo in Advanced NSCLC with EGFR Exon 20 Insertions – MARIPOSA – Amivantamab Plus Lazertinib Versus Osimertinib as First-line Treatment in EGFR-mutated Advanced […]
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet-
#ESMO23 Lung II Highlights w/ @AlexSpiraMDPhD - #PAPILLON - #MARIPOSA - #MARIPOSA2 - #LIBRETTO431 Full 📢: - https://t.co/UoegMXkdPK - https://t.co/IJYYXsTfq9 - Also on the “Oncology Brothers” podcast GI to follow! #MedTwitter #OncTwitter @myESMO #lcsm #LungCancer https://t.co/3D9Ub8fiOz
-
-
Mashup Score: 27
In discussion with Dr. Erika Hamilton, covering the ESMO 2023 Breast Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. Hamilton: – Keynote 756 – phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early stage, ER+/HER2- breast cancer, with better pCR […]
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet-
#ESMO23 Breast Ca Highlights w/ @ErikaHamilton9 - #KN756 - #TROPIONBreast01 - #KN522 Full discussion: - https://t.co/PJOBntkWe1 - https://t.co/ukvCupAM8Y - Also on the “Oncology Brothers” podcast Lung II & GI to follow! #MedTwitter #OncTwitter @myESMO #bcsm #OncEd https://t.co/X3Bn1zD7IS
-
-
Mashup Score: 36ESMO 2023 GU Cancer Highlights – SunRISE-1, EV-302, PSMAfore - 6 month(s) ago
In discussion with Dr. Rana McKay, covering the ESMO 2023 GU Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. McKay: – SunRISE-1 – TAR-200 in Combination with Cetrelimab Versus TAR-200 Versus Cetrelimab in NMIBC unpresponsive to BCG – with TAR-200 mono therapy achieving 77% overall complete response rate […]
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet-
#ESMO23 GU Highlights w/ @DrRanaMcKay - #SunRISe1 - #EV302 - #PSMAfore Full discussion: - https://t.co/fQNcBe37PK - https://t.co/dgh6AFviTm - Also on the “Oncology Brothers” podcast Breast, GI, Lung II to follow! #gusm #MedTwitter #OncTwitter @myESMO #bladdercancer https://t.co/Us6y2tAgr0
-
-
Mashup Score: 34ESMO 2023 GU Cancer Highlights – SunRISE-1, EV-302, PSMAfore - 6 month(s) ago
In discussion with Dr. Rana McKay, covering the ESMO 2023 GU Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. McKay: – SunRISE-1 – TAR-200 in Combination with Cetrelimab Versus TAR-200 Versus Cetrelimab in NMIBC unpresponsive to BCG – with TAR-200 mono therapy achieving 77% overall complete response rate […]
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet-
#ESMO23 GU Highlights w/ @DrRanaMcKay - #SunRISe1 - #EV302 - #PSMAfore Full discussion: - https://t.co/fQNcBe37PK - https://t.co/dgh6AFviTm - Also on the “Oncology Brothers” podcast Breast, GI, Lung II to follow! #gusm #MedTwitter #OncTwitter @myESMO #bladdercancer https://t.co/Us6y2tAgr0
-
-
Mashup Score: 32ESMO 2023 GU Cancer Highlights – SunRISE-1, EV-302, PSMAfore - 6 month(s) ago
In discussion with Dr. Rana McKay, covering the ESMO 2023 GU Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. McKay: – SunRISE-1 – TAR-200 in Combination with Cetrelimab Versus TAR-200 Versus Cetrelimab in NMIBC unpresponsive to BCG – with TAR-200 mono therapy achieving 77% overall complete response rate […]
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet-
#ESMO23 GU Highlights w/ @DrRanaMcKay - #SunRISe1 - #EV302 - #PSMAfore Full discussion: - https://t.co/fQNcBe37PK - https://t.co/dgh6AFviTm - Also on the “Oncology Brothers” podcast Breast, GI, Lung II to follow! #gusm #MedTwitter #OncTwitter @myESMO #bladdercancer https://t.co/Us6y2tAgr0
-
-
Mashup Score: 28ESMO 2023 Lung Cancer Highlights – Keynote 671, ALINA, TropionLung01 - 6 month(s) ago
In discussion with Dr. Joshua Reuss, covering the ESMO 2023 Lung Cancer Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Reuss: – Keynote 671 – perioperative approach in non-small cell lung cancer with pembrolizumab and cisplatin based chemo combination, with positive OS data – ALINA – resectable non-small cell […]
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet-
#ESMO23 Lung Ca Part I Highlights w/ @Joshua_Reuss - #KN671 - #ALINA - #TropionLung01 Full discussion: - https://t.co/1U7ac4Ljuw - Also on the “Oncology Brothers” podcast GU, Breast Ca, GI, and Lung II to follow! #LCSM #MedTwitter #OncTwitter @myESMO #OncEd #LCAM https://t.co/aiLRDOG6ie
-
-
Mashup Score: 5How to Treat Cutaneous Melanoma - Deep Dive with Dr. Sapna Patel - 7 month(s) ago
In discussion with Dr. Sapna Patel, Associate Professor, Director of the Uveal Melanoma, and Melanoma Fellowship Program Director at the MD Anderson Cancer Center we discuss how to treat Cutaneous Melanoma and important nuances from Community Oncology perspective. – Management of Stage 0/IA melanoma – where management is mainly surgery – Who is the most […]
Source: oncbrothers.comCategories: Latest Headlines, Partners & KOLsTweet-
w/@DrSapnaPatel we🗣️SoC for #Melanoma & key📝 to focus on in the community: - Adj IO Vs BRAF-MEKi - Switch Rx - #CTLA4 Full discussion: - https://t.co/dfFPLFjNcg - Also on the “Oncology Brothers” podcast #MedTwitter #OncTwitter #OncEd #Oncology @CureMelanoma @SWOG https://t.co/dPrnwhC2pL
-
-
Mashup Score: 18How to Treat Chronic Lymphocytic Leukemia (CLL) with Dr. Jeff Sharman – ONC Brothers - 8 month(s) ago
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and…
Source: oncbrothers.comCategories: Latest Headlines, Partners & KOLsTweet-
w/@jeff_sharman we🗣️SoC for #CLL & key📝 to 🔍 in the community: - Fixed⏰Rx vs. BTKi - #Obinutuzumab/#Rituximab - #Venetoclax management Full discussion: - https://t.co/YuEQBXnZHX - Also on the “Oncology Brothers” podcast #Leusm #HemeTwitter #MedTwitter #OncTwitter https://t.co/n76iML2HOm
-
#ESMO23 GI Highlights w/ @rachnatshroff - #CodeBreak300 - #CABINET - #GASTFOX Full 📢: - https://t.co/oO0ErxWu5B - https://t.co/bqb1o0FiD7 - Also on the “Oncology Brothers” podcast #MedTwitter #OncTwitter @myESMO #gism #crcsm @TargetedOnc https://t.co/yTRCLR3vYq